The Eurofins Network Announces Availability of Real-Time PCR Assay for the Identification of the Mpox Virus (Formerly Monkeypox), as WHO Declares Mpox a Public Health Emergency of International Concern and Health Authorities Recommend Increased...
2024年8月24日 - 5:24AM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
The Eurofins Network Announces Availability
of Real-Time PCR Assay for the Identification of the Mpox Virus
(Formerly Monkeypox), as WHO Declares Mpox a Public Health
Emergency of International Concern and Health Authorities Recommend
Increased Testing
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical
testing, announces the availability of its innovative PCR assay for
the simultaneous qualitative detection of the mpox virus and its
differentiation from other viruses from the orthopox family
(smallpox, cowpox, buffalopox, etc.) - the Mplex Mpox, Orthopox
assay.
European Centre for Disease Prevention and Control Director
Pamela Rendi-Wagner has noted that the 2024 outbreak of mpox in
several African countries, which WHO has declared a Public Health
Emergency of International Concern1, is likely to lead to “more
sporadic imported cases to the European continent”2, which will
require monitoring, testing and diagnostics support.
Early detection, surveillance and data is essential to efficient
infectious disease control. Mplex Mpox, Orthopox real-time PCR
assay was developed by Gold Standard Diagnostics Frankfurt GmbH,
part of the international network of Eurofins companies, in
response to the 2022 mpox epidemic. The PCR assay has been
evaluated and validated by the Institute of Health Carlos III
(ISCIII) in Spain and the French National Reference Center (CNR-LE)
and is immediately available as an RUO assay.
This 2024 outbreak is linked to the MPXV Clade I sublineage, a
virus variant that carries a genome deletion affecting binding
sites for primers and probes in certain real-time PCR assays,
potentially leading to assay failure. The Gold Standard Diagnostics
Mplex Mpox, Orthopox assay remains unaffected by this deletion
based on bioinformatic analysis.
Eurofins is making this new assay available to its laboratories
serving health authorities around the world where required and
applicable and has set aside test kit contingents for donation to
African countries’ health authorities who may need these tests.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E.
network of independent companies believes that it is a global
leader in food, environment, pharmaceutical and cosmetic product
testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one
of the market leaders in certain testing and laboratory services
for genomics, and in the support of clinical studies, as well as in
biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
The Eurofins network has grown very strongly since its inception
and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its
companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients
unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext
Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg
ERF FP).
Until it has been lawfully made public widely by Eurofins
Scientific S.E. through approved distribution channels, this
document contains inside information for the purpose of Regulation
(EU) 596/2014 of the European Parliament and of the Council of 16
April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific S.E.’s management as of the date of this
release. These forward-looking statements are not guarantees for
future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific S.E. disclaims any
intent or obligation to update any of these forward-looking
statements and estimates. All statements and estimates are made
based on the information available to the Company’s management as
of the date of publication, but no guarantees can be made as to
their completeness or validity.
_______________________________ 1 WHO declares mpox virus a
public health emergency of international concern | UN News 2 Mpox
Africa Outbreak Needs More Testing, Europe CDC Chief Says -
Bloomberg
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240823183747/en/
For further information please contact:
order@goldstandarddiagnostics.eu For more information, please
visit www.eurofins.com or contact: Investor Relations
Eurofins Scientific SE Phone: +32 2 766 1620 E-mail:
ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 9 2024 まで 10 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 10 2023 まで 10 2024